Jazayeri Seyed Behzad, Dehghanbanadaki Hojat, Hosseini Mahdie, Taghipour Pourya, Bacchus Michael W, Di Valerio Elizabeth A, Sarabchian Elnaz, Balaji K C, Bandyk Mark
Department of Urology, University of Florida College of Medicine, Jacksonville, FL, USA.
Department of Urology, University of Florida College of Medicine, Gainesville, FL, USA.
Curr Urol. 2023 Dec;17(4):262-267. doi: 10.1097/CU9.0000000000000214. Epub 2023 Jun 24.
Vesical Imaging-Reporting and Data System (VI-RADS) was developed as a structured reporting tool to anticipate the possibility of muscle invasion. This study is aimed to investigate the diagnostic accuracy of VI-RADS for discriminating T2 from T1 bladder cancer.
Scopus, Web of Science, PubMed, and Embase were searched on October 4, 2021, for studies with the following characteristics: (1) bladder cancer patient population, (2) VI-RADS as an index test, (3) retransurethral resection of bladder tumor/cystectomy as a reference, and (4) adequate VI-RADS score data for T1 and T2 lesions. The analyses were performed using the binary regression model of MIDAS in Stata.
Six studies with 624 magnetic resonance imaging reports were included. The receiver operating characteristics curve for differentiation of T2 from T1 bladder cancer showed an area under the curve of 0.93 (95% confidence interval [CI], 0.91-0.95) for a VI-RADS ≥3 and 0.75 (95% CI, 0.71-0.79) for a VI-RADS ≥4. A VI-RADS ≥3 showed high sensitivity of 93% (95% CI, 85%-97%), specificity of 61% (95% CI, 30%-86%), positive likelihood ratio of 2.4 (95% CI, 1.1-5.3), and negative likelihood ratio of 0.11 (95% CI, 0.05-0.24). A total of 10.4% of T2 lesions were scored as VI-RADS 2, while 10% of T1 lesions were scored as VI-RADS 4 or 5.
The VI-RADS ≥3 has high accuracy and sensitivity for detecting muscle invasion in borderline populations of T1 or T2 bladder cancer. Thus, the VI-RADS could be a good non-invasive screening test for the detection of T2 urothelial lesions.
膀胱影像报告和数据系统（VI-RADS）是作为一种结构化报告工具而开发的，用于预测肌肉浸润的可能性。本研究旨在调查VI-RADS鉴别T2期与T1期膀胱癌的诊断准确性。
于2021年10月4日在Scopus、科学网、PubMed和Embase数据库中检索具有以下特征的研究：（1）膀胱癌患者群体；（2）以VI-RADS作为指标检测；（3）以膀胱肿瘤经尿道再切除/膀胱切除术作为参考；（4）有足够的T1期和T2期病变的VI-RADS评分数据。使用Stata中的MIDAS二元回归模型进行分析。
纳入了6项研究，共624份磁共振成像报告。鉴别T2期与T1期膀胱癌的受试者操作特征曲线显示，VI-RADS≥3时曲线下面积为0.93（95%置信区间[CI]，0.91-0.95），VI-RADS≥4时曲线下面积为0.75（95%CI，0.71-0.79）。VI-RADS≥3时显示出高敏感性，为93%（95%CI，85%-97%），特异性为61%（95%CI，30%-86%），阳性似然比为2.4（95%CI，1.1-5.3），阴性似然比为0.11（95%CI，0.05-0.24）。共有10.4%的T2期病变评分为VI-RADS 2，而10%的T1期病变评分为VI-RADS 4或5。
VI-RADS≥3在检测T1期或T2期膀胱癌临界人群的肌肉浸润方面具有较高的准确性和敏感性。因此，VI-RADS可能是检测T2期尿路上皮病变的一种良好的非侵入性筛查试验。
